ACT CABERGOLINE
As listed in the register: ACT CABERGOLINE
0.5 mg · tablet
- Prescription only
- Urinary and reproductive system, hormones
- Active substance
- Cabergoline
- Made by
- Teva Canada Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Cabergoline). It describes the substance, not this exact product.
Cabergoline is an ergot derivative and dopamine receptor agonist with a high affinity for D2 receptors.
Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs.
Cabergoline is extensively metabolized, predominately via hydrolysis of the acylurea bond or the urea moiety.
After oral dosing of radioactive cabergoline to 5 healthy volunteers, approximately 22% and 60% of the dose was excreted within 20 days in the urine and feces, respectively.
Effect of Food: High-fat food did not alter the pharmacokinetics of cabergoline [see Dosage and Administration (2.2) ].
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-30
Safety of the active substance
From the US prescribing label for the same active substance (Cabergoline). It describes the substance, not this exact product.
- CABERGOLINE is contraindicated in patients with:.
- Uncontrolled hypertension..
- Known hypersensitivity to ergot derivatives..
- History of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis, or history of pericardial fibrosis [see Warnings and Precautions (5.1) ]..
The most common adverse reactions (incidence >10%) are nausea, headache, and dizziness.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
Spain2 matching products
France6 matching products
Netherlands5 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Teva Canada Limited |
|---|---|
| Active substance | Cabergoline |
| Used in | Urinary and reproductive system, hormones |
| Strength | 0.5 mg |
| Form | tablet |
| Classification | G02CB03 · Urinary and reproductive system, hormones |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Dormant |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02301407 |
| DPD drug code | 78674 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.